3.300

+0.130 (+4.10%)
Range 3.180 - 3.470   (9.12%)
Open 3.250
Previous Close 3.170
Buy Price 3.200
Buy Volume 14
Sell Price 3.330
Sell Volume 9
Volume 1,830,471
Value -
Remark
Measurement Type Value
EPS (USD) -0.543
Trailing EPS (USD) -0.603
NAV (USD) 0.771
Cash In Hand (USD) 0.951
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 4.109
Price / Cash In Hand 3.333
Issued & Paid-up Shares 73,716,800
Treasury Shares -
Market Cap (M) 233.682
Par Value (USD) n.a.
Beta - 75 Days 0.149
R-Squared - 75 Days(%) 0.05
Beta - 500 Days 0.401
R-Squared - 500 Days(%) 1.02
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 20 Oct 2020 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Earnings

Release Date 09 Nov 2020
View All Events

About CTI BIOPHARMA CORP

CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company is concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. The Company is primarily focused on commercializing PIXUVRI (pixantrone) in the European Union for multiplies relapsed or refractory aggressive non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial of pacritinib for the treatment of myelofibrosis. PIXUVRI is a novel aza-anthracenedione derivative that is structurally related to anthracyclines and anthracenediones, but does not appear to be associated with the same level of cardiotoxic effects.

Loading Chart...